Sunday 18 October 2026
Export ATTO’s income statement to Excel — free account
Attovia Therapeutics, Inc.
ATTO
Insiders bought in the last twelve months.
13.73
1.05
−7.10%
Follow ATTO
| Jun '26 | Dec '25 | Jun '25 | |
|---|---|---|---|
P/S ratio |
0.00 | — | — |
P/FCF ratio |
0.00 | — | — |
P/Operating CF |
0.00 | — | — |
P/B ratio |
0.00 | — | — |
Price to Tangible BV |
0.00 | — | — |
EV/Sales |
0.00 | — | — |
EV/EBITDA |
0.00 | — | — |
EV/Operating CF |
0.00 | — | — |
EV/FCF |
0.00 | — | — |
Quick Ratio |
9.13 | 13.83 | — |
Current Ratio |
9.39 | 14.20 | — |
Net Debt/EBITDA |
5.28 | 0.00 | 0.00 |
Debt/Assets |
0.00% | 0.00% | — |
Debt/Equity |
0.00 | 0.00 | — |
Operating CF/Net income |
0.00 | — | 0.00 |
Research and Development Expense of Revenue |
4,210.22% | — | 0.00% |
Selling, General and Administrative Expense of Revenue |
734.89% | — | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | — |
Share Based Compensation of Revenue |
0.00% | — | — |
Graham Net Nets |
(1.67) | — | — |
Graham Number |
0.00 | — | — |
Free Cash Flow Yield |
0.00% | — | — |
Revenue per Share |
0.11 | — | 0.00 |
Operating CF per Share |
0.00 | — | 0.00 |
Capex per Share |
0.00 | — | 0.00 |
Free Cash Flow per Share |
0.00 | — | 0.00 |
Cash per Share |
27.17 | 0.00 | 0.00 |
Shareholders Equity per Share |
(34.33) | 0.00 | 0.00 |
Interest Debt per Share |
0.00 | — | 0.00 |
Book value per Share |
(34.33) | 0.00 | 0.00 |
EV/EBIT |
0.00 | — | — |
Capex to Sales |
0.00 | — | — |
Price to Operating Income |
0.00 | — | — |
| Other line items | |||
Working Capital |
105.79 | 145.29 | — |
Net Current Asset Value |
(155.41) | (117.03) | — |
Columns are period end dates · fundamentals updated 29 Sep 2026